didnt have time to try and listen to cc, was going to listen this eve. but if he Demopulos didn't show up, it would nt be the first time - he skipped some other conf awhile back, and sated because of health reasons. seems very odd, since thet hardy ever speak.
European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721
Date(s): 14-Apr-2015 7:01 AM
-- Patients with Thrombotic Microangiopathy Will Now Be Able to Receive Extended Treatment -
SEATTLE, April 14, 2015 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the presiding European regulatory authority has approved the company's investigational product OMS721 for compassionate use. OMS721 is Omeros' lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of thrombotic microangiopathies (TMAs), including atypical hemolytic uremic syndrome (aHUS). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain.
The two patients in the compassionate-use study suffer from aHUS and were enrolled in the first cohort of the Phase 2 clinical trial. Based on improvements across markers of disease activity in that cohort, the investigator requested that Omeros continue to provide OMS721 so that the patients could extend their treatments. Following regulatory approval, Omeros was pleased to release shipment of OMS721 to continue treatment of these patients.
Omeros' ongoing OMS721 Phase 2 study continues to progress through its dose-ranging phase. The second cohort of patients, which received a higher dose than the first cohort, has now completed treatment. Following a pre-planned data review by internal and external physicians, if the safety data from the second cohort are acceptable, a recommendation will be made to advance as scheduled to a third cohort at an even higher dose. This third cohort could begin dosing before the end of April.
[more in news release]
IMO, I don't think we need much more "unforeseen" news than just what's expected to be coming toward us anyway: European approval, rebalancing of Russell 2000, reasonable rate of adoption of Omidria by ophthalmologists, halfway decent Q3 earnings, and -- if all goes really well -- short squeeze. And that ignores any possible good news on the rest of the drug pipeline. By the way, kudos on seeing the upturn heading into tomorrow's conference.
didnt mean "clown" in a bad way, and I hope your correct in the 80pps by eoy, but something unforseen would need to happen to achieve that hefty markt cap increase
Feel free to call me a clown, if that makes you feel good. Just remember that you read it here first. There are excellent reasons to conclude that OMER is very seriously undervalued and that the investment world will soon wake up to that fact.
Sentiment: Strong Buy
52 week high was 27.64 so this is not over valued with expected q2 earnings. I think we will see $30 before July 4 and if earnings are good it will move north.
Sure I'm being exuberant, but I think there's a real shot: that's roughly a $3bn valuation. All that has to happen is that some institutional investors start to believe that Omidria will eventually grow to become standard of use in cataract surgery. The short squeeze will serve to accelerate the rise in price.
Sentiment: Strong Buy
the rise in pps today probably has nothing to do with Omeros - virtually EVERY biotec stock is up today.
As the previous topic said, there are 8.4m shares that don't want your prediction to happen.
I think Q2 sales will be strong. Per prior CC some of the sales staff started calling during August 2014. The additional 20 sales staff started going to the field late Jan (the initial sales staff of 20 were in the field prior to Jan 2015). I think the ramp-up has already occurred (per prior CC they will target the physician groups and individual docs that perform majority of the operations).
Alan Ross ? He is a great musician. Bought 4 cds recently. He started together with Eric Clapton then moved apart.